The endothelium modulates adrenergic neurotransmission to canine pulmonary arteries and veins.
We tested the postulate that endothelium-derived relaxing factor (EDRF) modulates adrenergic neuroeffector transmission in isolated canine pulmonary arteries and veins, using the technique of superfusion and measurement of the efflux of [2-14C]NE during transmural nerve stimulation at 1, 2, 4, 8, 16 and 32 Hz for 10 and 30 min. In endothelium-rubbed artery and vein the contractile responses to low frequency nerve stimulation were enhanced, when compared to those from endothelium rubbed blood vessels. Transmural nerve stimulation of endothelium competent arteries and veins for 10 min released less [2-14C]NE than denuded arteries and veins, especially at 1, 2 and 4 Hz, with smaller differences evident at higher frequencies (16 and 32 Hz) of stimulation. Superfusion of endothelium rubbed blood vessels with effluent from canine thoracic aorta decreased the release of [2-14C]NE during nerve stimulation. These findings suggest that the endothelium and EDRF can inhibit release of adrenergic neurotransmitter from canine pulmonary arteries and veins. The endothelium may act as an endogenous modulator of adrenergic neurotransmission to canine vascular smooth muscle.
Greenberg
S
S
University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Department of Physiology, Newark 07103.
Diecke
F P
FP
Peevy
K
K
Tanaka
T P
TP
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism; D001685:Biological Factors / Q000494:pharmacology; D001949:Bretylium Compounds / Q000494:pharmacology; D004285:Dogs; D004558:Electric Stimulation; D004730:Endothelium, Vascular / Q000187:drug effects / Q000294:innervation* / Q000378:metabolism; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009569:Nitric Oxide; D009638:Norepinephrine / Q000378:metabolism; D010208:Papaverine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011651:Pulmonary Artery / Q000187:drug effects / Q000294:innervation; D011667:Pulmonary Veins / Q000187:drug effects / Q000294:innervation; D013564:Sympathetic Nervous System / Q000502:physiology*; D009435:Synaptic Transmission; D013779:Tetrodotoxin / Q000494:pharmacology
D001685:Biological Factors; D001949:Bretylium Compounds; D009569:Nitric Oxide; D013779:Tetrodotoxin; D010208:Papaverine; D011464:Epoprostenol; D000109:Acetylcholine; D009638:Norepinephrine; D011224:Prazosin